The Study of Infection and Cell Inflammation in Peritoneal Dialysate
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A progressive decline of plasma triggering receptor expressed on myeloid cells-1 (TREM-1) concentration indicates a favorable clinical evolution during the recovery phase of sepsis. The expression of TREM-1 in dialysate of peritoneal dialysis patients was not yet documented. We will collect the dialysate of peritonitis in peritoenal dialysis patients and analyze the time serial change.
| Condition |
|---|
|
Peritonitis Kidney Failure |
| Study Type: | Observational |
| Study Design: | Observational Model: Defined Population Primary Purpose: Screening Time Perspective: Cross-Sectional Time Perspective: Prospective |
| Estimated Enrollment: | 100 |
| Study Start Date: | June 2005 |
| Estimated Study Completion Date: | June 2009 |
The triggering receptor expressed on myeloid cells-1 (TREM-1) is a member of the immunoglobulin superfamily, and its expression is upregulated on phagocytic cells in the presence of bacteria or fungi (1). Several experiments by Bouchon and colleagues showed that TREM-1 mediates the acute inflammatory response to microbial products. Human tissues infected with bacteria are infiltrated with neutrophils and macrophages that express high levels of TREM-1. Conversely, TREM-1 is only weakly expressed in samples from patients with noninfectious inflammatory disorders. In addition, TREM-1 is shed from the membrane of activated phagocytes and can be found in a soluble form in body fluids. The presence of a soluble form of TREM-1 in samples of bronchoalveolar lavage fluid from mechanically ventilated patients has been shown to be a good indicator of infectious pneumonia. During sepsis, a progressive decline of plasma sTREM-1 concentration indicates a favorable clinical evolution during the recovery phase of sepsis. In addition, baseline sTREM-1 level may prove useful in predicting outcome of septic patients. We will collect the dialysate of peritonitis in peritoneal dialysis patients and analyze the time serials change.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
peritoneal dialysis patients, dialysis period for more than 3 months.
Exclusion Criteria:
age younger than 18 years old, Pregnant or lactating women. (Pre-menopause women, capable of bearing children will undergo pregnancy test)
Contacts and Locations| Contact: Vin-cent Wu, MD | 886-2-2356-2000 | walt-wu@yahoo.com.tw |
| Taiwan | |
| National Taiwan University Hospital | Recruiting |
| Taipei, Taiwan | |
| Contact: Vincent Wu, MD 886-2-2356-2000 walt-wu@yahoo.com.tw | |
| Study Chair: | Kwan-Dun Wu, MD, PhD | National Taiwan University |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00173485 History of Changes |
| Other Study ID Numbers: | 9461700636 |
| Study First Received: | September 12, 2005 |
| Last Updated: | November 23, 2005 |
| Health Authority: | Taiwan: Department of Health |
Keywords provided by National Taiwan University Hospital:
|
peritonitis, peritoneal dialysis, dialysate |
Additional relevant MeSH terms:
|
Peritonitis Renal Insufficiency Peritoneal Diseases |
Digestive System Diseases Kidney Diseases Urologic Diseases |
ClinicalTrials.gov processed this record on May 19, 2013